SINGAPORE-- India is not a member of the 12-nation Trans-Pacific Partnership, but its intellectual property rules governing pharmaceutical patents lie at the core of a dispute ginning up this year to reach a final agreement. India's resistance to relaxing its rules has been a model for the emerging-market members of the TPP to seek similar compulsory licensing arrangements for generic drugs.
Astellas tweaked its plans for Tuesday, the day a trial was set to start over an alleged scheme to delay generics of immune-suppressant drug Prograf. Instead of heading to court, the Japanese pharma agreed to settle a handful of lawsuits, it announced.
Teva finally has the Supreme Court Copaxone patent battle victory it's been waiting for--but that doesn't mean its legal journey is over.
India's state of Himachal Pradesh, known as Asia's pharmaceutical hub, is taking steps to make its bulk-drug industry more attractive to foreign and other investors, but finds attempting to do so a hard slog. The action, and that of other states, is considered key to reducing India's reliance on imports of active pharmaceutical ingredients, mainly from China.
India's intellectual-property police nixed a key patent on Gilead Sciences' hepatitis C drug Sovaldi, opening the door for cheap generic copies from domestic drugmakers such as Natco Pharma. It's the latest blow to a multinational drugmaker's ambitions in India, which remains one of the fastest-growing drug markets in the world.
Actavis is waiting eagerly to find out whether it can move forward with its plans to force patients over to a new, patent-protected version of blockbuster Alzheimer's treatment Namenda. And its waiting period just got shorter.
Novartis took its first big hit from new Diovan generics during last year's third quarter, when Ranbaxy Laboratories finally won approval for its exclusive generic of the blood pressure pill. And it was indeed a big hit: a 76% drop in U.S. sales for the franchise, to $97 million.
No luck for Sanofi in turning over a Plavix antitrust fine. A Paris appeals court has upheld the €40.6 million ($49.7 million) penalty for trying to keep doctors and pharmacists from prescribing or subbing copycat versions of the former blockbuster blood thinner, Law360 reports.
Not so fast, Teva. The generics giant--which last week said it was set to roll out copies of Pfizer blockbuster Celebrex--now has to put those plans on hold, as per a U.S. appeals court ruling.
Bayer was dealt a crushing blow in its ongoing fight to block generic sales of its cancer powerhouse Nexavar in India, as the country's Supreme Court ruled that an Indian generics group had the right to sell a copycat version of the drug.